Long COVID és ME/CFS: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• IL-6 1
• ACE2 0
• mTOR 0
• NLRP3 0
• PI3K 0
• TNF 0
• AMPK 0
• CD38 1
• GLP-1 0
• IL-15 1
• JAK 0
• MMP-9 0
• AKT 0
• APOE 0
• AQP4 0
• BDNF 0
• CD19 1
• CD40 0
• HIF-1 0
• HSP90 0
• IL-1 0
• IL-17 0
• NMDA 0
• PD-1 1
• SGLT2 0
• TFEB 0
• TP53 0
• VEGF 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · R01

  Developing Integration and Modeling Frameworks for Single-Cell and Bulk Transcriptomics to Analyze Atlas-Scale Cell-Resolved Immune Variation Across Infections and Vaccinations

  Yale University· New Haven, Egyesült Államok· 570 224 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NINDS · RF1

  The Central Role of mTOR in ME/CFS Pathogenesis.

  Simmaron Research Inc· Incline Village, Egyesült Államok· 780 000 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NINDS · R01

  Neuro-PASC (Brain Fog and Fatigue) is Caused by a Dysbiotic Gut Microbiome

  University of Texas Med Br Galveston· Galveston, Egyesült Államok· 625 273 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NINDS · R21

  Herpesvirus Reactivation as a Cause of Chronic Fatigue Following Coronavirus Infection

  University of Michigan at Ann Arbor· Ann Arbor, Egyesült Államok· 429 000 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NHLBI · R01

  Cardiometabolic Disease after COVID-19

  Vandeventer Place Research Foundation· Saint Louis, Egyesült Államok· 402 941 USD awarded in fiscal year 2026· until 2030. máj.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Navigating Work-Nonwork Boundaries in Hybrid Work: Exploring Career Trajectories and Intersectional Challenges for Professional Women (HYBWORKEXP)

  Ism Vadybos Ir Ekonomikos Universitetas Uab· Vilnius, Litvánia· EU contribution 196 976 EUR· until 2028. aug.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Nutrition AI for Well-Being and Social Inclusion (NutriWell)

  Innova Living· Sofia, Bulgária· EU contribution 499 629 EUR· until 2028. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Biological evidence and mechanism-based disease classification for the improved diagnosis, prognosis and treatment of ME/CFS (DISCOVER-ME)

  Medizinische Universitaet Wien· Wien, Ausztria· EU contribution 7 588 595 EUR· until 2030. jún.· 12 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Kefiran: Harnessing Exopolysaccharide bioActivities beneficiaL To Health (KHEALTH)

  Teagasc - Agriculture and Food Development Authority· Carlow, Írország· EU contribution 252 729 EUR· until 2028. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Housing, Inequality, and Price-Setting: Theory, Evidence, and Ramifications for the Macroeconomy (HIPSTERMacro)

  Stockholms Universitet· Stockholm, Svédország· EU contribution 1 504 353 EUR· until 2030. szept.

  The disease is named only in the funder's project summary, not in the title.

10 of 304 running projects, newest first. Listed amounts together: 219,7 M USD + 68,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

  NCT06171152· University of Chicago· Frissítve: 2026. márc. 30.

  “Study pending amendment”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

  NCT06171152· University of Chicago· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 7
• Organoids 1
• Mendelian Randomization Analysis 4
• Gene Expression Profiling 20
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 6
• Proteomics 40
• Metabolomics 20
• Mass Spectrometry 1
• Flow Cytometry 2
• Immunohistochemistry 2
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 49
• Machine Learning 32
• Deep Learning 5
• Cohort Studies 92
• Genome-Wide Association Study 11

• Genetic evidence that advanced COVID-19 accelerates longitudinal brain atrophy: A Mendelian randomization study.

  Medicine (Baltimore), 2026. jún.

• Mitochondria-Related Genome-Wide Mendelian Randomization Identifies Putatively Genes for Chronic Fatigue.

  Mol Neurobiol, 2026. ápr.

• Integrative multi-omics framework for causal gene discovery in Long COVID.

  PLoS Comput Biol, 2025. dec.

• Mendelian randomization analyses support causal relationships between COVID-19 and changes in brain structure and function.

  Eur Arch Psychiatry Clin Neurosci, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.